Profitability Recovery in the North American Gelatin Business
First written in FY2018. 6 of 17 entries say "Advanced", first in FY2019-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2018: 2 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Other".
- FY2026Declining North American sales alongside improved profitabilityAnnual report
「In North America, revenue declined because sales of inventory remaining after the production halt at Nitta Gelatin USA Inc., which had been recorded in the first quarter of the previous fiscal year, had ended, and sales of bovine-bone gelatin for soft capsules exported by Nitta Gelatin India Ltd. declined due to the impact of tariffs.」
In the North American business, inventory sales following the U.S. production halt ended, while sales of products exported from India declined due to the impact of tariffs. Meanwhile, consolidated operating profit was ¥4,664 million, helped by improved profitability in North America and elsewhere. - 2026-05-14AdvancedEarnings presentation materials
「Increase sales through expanded sales in Japan and the use of alliances in North America」
For the North American business, the forecast for the fiscal year ending March 2027 explicitly includes sales expansion through alliances, in addition to improved profitability following the previous production suspension. - FY2026-H1Completion of inventory sales and improved profitability following the production haltAnnual report
「In North America, sales of bovine-bone gelatin for soft capsules exported by Nitta Gelatin India Ltd. remained strong. However, revenue declined because sales of inventory remaining after the production halt at Nitta Gelatin USA Inc., which had been recorded in the previous interim consolidated accounting period, had ended.」
In North America, sales of bovine-bone gelatin exported from India were strong, but revenue declined after inventory sales following the U.S. production halt ended. Improved profitability coexisted with a decline in sales volume. - FY2025Improved profitability following the production haltAnnual report
「On the profit side, in addition to strong sales in Japan, improved profitability resulting from the production halt at NGU contributed to operating profit of ¥3,930 million, an increase of 114.0% year on year.」
Regarding the recovery of profitability in the North American business, the Group stated that improved profitability following the production halt, rather than recovery through continued production at NGU, contributed to the increase in operating profit. - FY2024-Q3ReframedAnnual report
「The Group decided to stop production at Nitta Gelatin USA Inc. on the grounds that streamlining the North American business and concentrating resources on growth areas would enhance the corporate value of the Group as a whole.」
The direction has shifted from seeking to restore profitability in the North American gelatin business through higher productivity and other measures to streamlining the North American business by stopping U.S. production and concentrating resources on growth areas while retaining Canadian production and the existing sales structure. - FY2024-Q2Diverging performance by application in North AmericaAnnual report
「Overseas, in North America, demand for collagen peptides was on a softening trend due to inflation, but revenue increased as sales of gelatin for capsules remained firm.」
In North America, demand for collagen peptides softened under the impact of inflation, while firm sales of gelatin for capsules drove higher revenue. Profitability recovery in the North American business continued to vary by application. - FY2023-Q3AdvancedAnnual report
「Overseas, collagen peptide sales remained strong in North America, but sales of beauty-use collagen peptides declined in Asia as economic stagnation, inflation and other factors dampened consumer sentiment. Meanwhile, sales of gelatin for capsules increased in North America and India as the COVID-19 pandemic heightened awareness of health promotion and prevention.」
Collagen peptide sales were strong in North America, and revenue from gelatin for capsules also increased in North America and India. Sales of beauty-use collagen peptides in Asia declined due to economic stagnation and inflation. - FY2023-Q1AdvancedAnnual report
「Overseas, revenue increased as collagen peptides benefited from strong demand in North America and strong sales in Asia of beauty-use collagen peptides marketed for their functional benefits, while demand for gelatin for capsules was also strong in North America and India as the COVID-19 pandemic heightened awareness of health promotion and prevention.」
Demand for beauty-use collagen peptides strengthened in North America, marking a shift to higher sales from the oversupply and sales declines reported through the previous fiscal year. Products marketed for their functional benefits also performed well in Asia. - FY2022-Q3North American beauty applications remained at the level of the same period of the previous yearAnnual report
「Overseas, revenue from beauty-use collagen peptide products in North America was at the same level as in the same period of the previous year.」
The Group stated that revenue from beauty-use collagen peptide products in North America was at the same level as in the same period of the previous year. - FY2022-Q1AdvancedAnnual report
「Overseas, collagen peptide revenue in North America increased, helped by a recovery in demand for beauty-use collagen peptide products and the expansion of sales of high-functionality collagen peptides.」
Demand for beauty-use collagen peptides recovered in North America, while the expansion of sales of high-functionality collagen peptides contributed to higher revenue. - FY2021Increase in capsule applications, decline in beauty applicationsAnnual report
「Overseas, in North America, sales of gelatin for soft capsules increased as the spread of COVID-19 heightened awareness of health maintenance and prevention. On the other hand, sales of beauty collagen peptide products at retail outlets declined, resulting in lower revenue.」
In the North American business, sales of gelatin for soft capsules increased, while retail sales of beauty collagen peptides declined, with continued divergence by application in the recovery of profitability. - FY2021-Q2WorsenedAnnual report
「Overseas, collagen peptide revenue declined in North America due to slowing market growth and the impact of COVID-19. Meanwhile, sales of gelatin for soft capsules increased on firm demand for health food capsules.」
In North America, revenue declined due to slower market growth for collagen peptides and the impact of COVID-19, worsening sales-related challenges to restoring profitability. Sales of gelatin for soft capsules, however, increased. - FY2021-Q1WorsenedAnnual report
「Overseas, collagen peptide revenue declined in North America due to oversupply of collagen peptides and lower sales of beauty supplements.」
In North America, oversupply of collagen peptides and lower sales of beauty supplements continued to pose sales-related challenges to restoring profitability. - FY2020-Q2AdvancedAnnual report
「Overseas, the collagen peptide market for beauty applications expanded in North America, while demand for capsules for health foods remained firm. In India as well, sales increased as demand for capsules for pharmaceutical and health food applications remained firm.」
In North America, the beauty-use collagen peptide market expanded and demand for capsules for health foods remained firm. In India, sales of capsules for pharmaceutical and health food applications increased. - FY2019-Q3RestatedAnnual report
「Overseas, sales for capsule applications in the North American market remained firm as market conditions recovered. In beauty applications, revenue increased as sales of collagen peptides manufactured at the North American plant expanded.」
The Group reported firm sales of collagen peptides for capsule applications in North America and increased sales of collagen peptides manufactured at the North American plant, continuing its disclosure on the status of profitability recovery in the North American business. - FY2019-Q1AdvancedAnnual report
「Competition in the capsule market remained severe in North America, resulting in lower revenue. Profit increased, helped by the stabilization of production at the North American and Indian plants.」
While sales challenges remained in North America, profit from the gelatin business increased as production stabilized at the North American and Indian plants, indicating tangible progress toward restoring profitability. - FY2018First statedAnnual report
「In the gelatin business, the Group will make every effort to restore profitability in North America by reviewing its sales strategy and improving production efficiency.」
In response to declining profitability caused by higher raw material prices and intensifying competition in North America, the Group identified restoring profitability through a review of its sales strategy and improved production efficiency as a specific issue.